JGC
TXMD icon

J. Goldman & Co’s TherapeuticsMD TXMD Stock Holding History

J. Goldman & Co’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,500
Closed -$1.48M – 309
2018
Q3 		$1.48M Buy
+4,500
New +$1.38M 0.1% 167
2018
Q1 		– Sell
-17,200
Closed -$5.19M – 436
2017
Q4 		$5.19M Buy
+17,200
New +$4.79M 0.27% 100
2017
Q3 		– Sell
-1,000
Closed -$264K – 403
2017
Q2 		$264K Buy
+1,000
New +$250K 0.01% 266

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

J. Goldman & Co's TXMD Position: Q4 2025 in Review

J. Goldman & Co sold out of TherapeuticsMD (TXMD) in Q4 2025, closing a stake of 13,562 shares — an estimated $14.6K sold.

J. Goldman & Co first reported a position in TXMD in Q3 2015 and held it in 32 quarters. The position peaked at $9.65M in Q1 2019. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.

  • J. Goldman & Co reported no remaining TherapeuticsMD position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 13,562 TherapeuticsMD shares in Q4 2025, an estimated $14.6K.
  • J. Goldman & Co first reported a position in TherapeuticsMD in Q3 2015 and held it in 32 quarters.
  • J. Goldman & Co's TherapeuticsMD position peaked at $9.65M in Q1 2019.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.